Hodgkin's disease: controversies and challenges for the future.
Tura
S
S
Istituto di Ematologia, L. e A. Seràgnoli, Università di Bologna, Italy.
Canellos
G
G
Goldstone
A
A
Longo
D
D
McMillan
A
A
Urba
W
W
Zinzani
P L
PL
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004351:Drug Resistance; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D009378:Neoplasms, Multiple Primary; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction; D016879:Salvage Therapy; D013156:Splenectomy / Q000009:adverse effects; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014747:Vinblastine; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone